COMPASS Pathways (CMPS) Scheduled to Post Quarterly Earnings on Wednesday

COMPASS Pathways (NASDAQ:CMPS) is scheduled to be posting its quarterly earnings results after the market closes on Wednesday, May 8th. Analysts expect COMPASS Pathways to post earnings of ($0.52) per share for the quarter. Parties that wish to listen to the company’s conference call can do so using this link.

COMPASS Pathways (NASDAQ:CMPS) last posted its earnings results on Thursday, February 29th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.37) by ($0.16). On average, analysts expect COMPASS Pathways to post $-2 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

COMPASS Pathways Stock Performance

COMPASS Pathways stock traded up $0.13 during midday trading on Monday, hitting $8.66. The stock had a trading volume of 82,111 shares, compared to its average volume of 660,753. COMPASS Pathways has a 52-week low of $5.01 and a 52-week high of $12.75. The firm’s fifty day moving average is $9.51 and its two-hundred day moving average is $8.51. The company has a current ratio of 13.33, a quick ratio of 13.33 and a debt-to-equity ratio of 0.14. The company has a market capitalization of $536.40 million, a PE ratio of -3.62 and a beta of 2.39.

Insider Buying and Selling

In other news, Director George Jay Goldsmith sold 15,740 shares of the company’s stock in a transaction that occurred on Tuesday, March 12th. The stock was sold at an average price of $10.58, for a total transaction of $166,529.20. Following the completion of the transaction, the director now directly owns 4,079,107 shares of the company’s stock, valued at $43,156,952.06. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other COMPASS Pathways news, Director Ekaterina Malievskaia sold 19,853 shares of the business’s stock in a transaction dated Tuesday, February 6th. The shares were sold at an average price of $10.59, for a total value of $210,243.27. Following the sale, the director now directly owns 4,144,994 shares in the company, valued at $43,895,486.46. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director George Jay Goldsmith sold 15,740 shares of the firm’s stock in a transaction dated Tuesday, March 12th. The shares were sold at an average price of $10.58, for a total transaction of $166,529.20. Following the transaction, the director now owns 4,079,107 shares of the company’s stock, valued at approximately $43,156,952.06. The disclosure for this sale can be found here. Insiders have sold 140,601 shares of company stock valued at $1,338,911 in the last quarter. Company insiders own 4.25% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on the stock. Cantor Fitzgerald restated an “overweight” rating on shares of COMPASS Pathways in a research note on Tuesday, April 30th. Morgan Stanley initiated coverage on shares of COMPASS Pathways in a research report on Monday, April 1st. They set an “overweight” rating and a $30.00 price target on the stock. Finally, HC Wainwright reiterated a “buy” rating and set a $120.00 price target on shares of COMPASS Pathways in a research report on Friday, March 1st. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat, COMPASS Pathways presently has a consensus rating of “Buy” and an average target price of $47.40.

About COMPASS Pathways

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.